RankAlpha logo
Back to Rankings

VKTX

Viking TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Positive injectable maintenance data and initiation of oral Phase 3 give VK2735 multiple ways to differentiate if larger trials reproduce efficacy and tolerability. These remain development-stage possibilities, not established commercial outcomes.
Posture
Defensive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-10-28 · AMC.
What can break
Part 1 maintenance findings came from an approximately 180-person study with a 12-week maintenance period; larger and longer studies may not replicate the result. [#PR-2026-09-22] company results
Momentum
10
Value
41
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $42.00 · Bear $13.00Analysis 2026-10-23; returns require an exact persisted reference.
Earnings
2026-10-28 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-23 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $95.05
Why
Momentum10 · Δ7d -8.8
Value41 · Δ7d -0.1
Sentiment56 · Δ7d -31.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-10-28 · AMC.
  • • Sentiment remains the lead driver in the composite, 7D delta -31.3.

Contradictions & invalidation

  • • Part 1 maintenance findings came from an approximately 180-person study with a 12-week maintenance period; larger and longer studies may not replicate the result. [#PR-2026-09-22] company results
  • • September's financing strengthened funding but issued shares and convertible debt, creating dilution and leverage considerations. The supplied September 28 8-K note establishes filing timing; the company release supplies the financing terms. [#8-K-2026-09-28] [#PR-2026-09-28] company financing release
  • • Large, long pivotal trials create execution and safety risk.

Catalyst clock

2026-10-28 · AMC

Q3 results are still pending—not a post-earnings review

Lead driver: Sentiment · See AI snapshot
Momentum
10
8% active weight
Current posture
7d trendSoftening
Δ7d
-8.8
Δ21d
-50.4
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
56
45% active weight
Current posture
7d trendSoftening
Δ7d
-31.3
Δ21d
-16.4
Why this grade

Composite grade D. Momentum 9.9 / Value 40.6 / Sentiment 56.4

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-23. Scenario method

B+
Bull case
25%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
Most likely
B
Base case
40%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$3.1B
Beta
0.76
Shares Out
127.17M
P/E (TTM) · Derived
-7.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.69
Rev YoY
-
EPS YoY
+88.3%
Gross Margin
-
Op Margin
-
Net Debt
-$705.6M
Current Ratio
4.72
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data